Comprehensive Evaluation System for Post-Metabolic Activity of Potential Thyroid-Disrupting Chemicals
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Endocrine-disrupting chemicals (EDCs) are compounds that disturb hormonal homeostasis by binding to receptors. EDCs are metabolized through hepatic enzymes, causing altered transcriptional activities of hormone receptors, and thus necessitating the exploration of the potential endocrinedisrupting activities of EDC-derived metabolites. Accordingly, we have developed an integrative workflow for evaluating the post-metabolic activity of potential hazardous compounds. The system facilitates the identification of metabolites that exert hormonal disruption through the integrative application of an MS/MS similarity network and predictive biotransformation based on known hepatic enzymatic reactions. As proof-of-concept, the transcriptional activities of 13 chemicals were evaluated by applying the in vitro metabolic module (S9 fraction). Identified among the tested chemicals were three thyroid hormone receptor (THR) agonistic compounds that showed increased transcriptional activities after phase I+II reactions (T3, 309.1 ± 17.3%; DITPA, 30.7 ± 1.8%; GC-1, 160.6 ± 8.6% to the corresponding parents). The metabolic profiles of these three compounds showed common biotransformation patterns, particularly in the phase II reactions (glucuronide conjugation, sulfation, GSH conjugation, and amino acid conjugation). Data-dependent exploration based on molecular network analysis of T3 profiles revealed that lipids and lipid-like molecules were the most enriched biotransformants. The subsequent subnetwork analysis proposed 14 additional features, including T4 in addition to 9 metabolized compounds that were annotated by prediction system based on possible hepatic enzymatic reaction. The other 10 THR agonistic negative compounds showed unique biotransformation patterns according to structural commonality, which corresponded to previous in vivo studies. Our evaluation system demonstrated highly predictive and accurate performance in determining the potential thyroid-disrupting activity of EDC-derived metabolites and for proposing novel biotransformants.
Abstract
Endocrine-disrupting chemicals (EDCs) are compounds that disturb hormonal homeostasis by binding to receptors. EDCs are metabolized through hepatic enzymes, causing altered transcriptional activities of hormone receptors, and thus necessitating the exploration of the potential endocrinedisrupting activities of EDC-derived metabolites. Accordingly, we have developed an integrative workflow for evaluating the post-metabolic activity of potential hazardous compounds. The system facilitates the identification of metabolites that exert hormonal disruption through the integrative application of an MS/MS similarity network and predictive biotransformation based on known hepatic enzymatic reactions. As proof-of-concept, the transcriptional activities of 13 chemicals were evaluated by applying the in vitro metabolic module (S9 fraction). Identified among the tested chemicals were three thyroid hormone receptor (THR) agonistic compounds that showed increased transcriptional activities after phase I+II reactions (T3, 309.1 ± 17.3%; DITPA, 30.7 ± 1.8%; GC-1, 160.6 ± 8.6% to the corresponding parents). The metabolic profiles of these three compounds showed common biotransformation patterns, particularly in the phase II reactions (glucuronide conjugation, sulfation, GSH conjugation, and amino acid conjugation). Data-dependent exploration based on molecular network analysis of T3 profiles revealed that lipids and lipid-like molecules were the most enriched biotransformants. The subsequent subnetwork analysis proposed 14 additional features, including T4 in addition to 9 metabolized compounds that were annotated by prediction system based on possible hepatic enzymatic reaction. The other 10 THR agonistic negative compounds showed unique biotransformation patterns according to structural commonality, which corresponded to previous in vivo studies. Our evaluation system demonstrated highly predictive and accurate performance in determining the potential thyroid-disrupting activity of EDC-derived metabolites and for proposing novel biotransformants.
참고문헌 (50)
- Tabb MM, "New modes of action for endocrine-disrupting chemicals", Mol. Endocrinol, 20, pp.475~482 (2006)
- Lee HR, "Molecular mechanism (s) of endocrine‐disrupting chemicals and their potent oestrogenicity in diverse cells and tissues that express oestrogen receptors", J. Cell. Mol. Med, 17, pp.1~11 (2013)
- Schug TT, "Endocrine disrupting chemicals and disease susceptibility", J. Steroid Biochem. Mol. Biol, 127, pp.204~215 (2011)
- Lauretta R, "Endocrine disrupting chemicals: effects on endocrine glands", Front. Endocrinol, 10, pp.178~ (2019)
- OECD, "OECD in vitro screens (Conceptual Framework Level 2)", ~ (2018)
- Gelbke H, "OECD test strategies and methods for endocrine disruptors", Toxicology, 205, pp.17~25 (2004)
- Bernal J, "Action of thyroid hormone in brain", J. Endocrinol. Investig, 25, pp.268~288 (2002)
- Boas M, "Thyroid effects of endocrine disrupting chemicals", Mol. Cell. Endocrinol, 355, pp.240~248 (2012)
- Browne P, "OECD approaches and considerations for regulatory evaluation of endocrine disruptors", Mol. Cell. Endocrinol, 504, pp.110675~ (2020)
- Jeon BK, "A systematic approach to metabolic characterization of thyroid-disrupting chemicals and their in vitro biotransformants based on prediction-assisted metabolomic analysis", J. Chromatogr. A, 1649, pp.462222~ (2021)
- J Richardson S, "Efficiency in drug discovery: liver S9 fraction assay as a screen for metabolic stability", Drug Metab. Lett, 10, pp.83~90 (2016)
- Doke SK, "Alternatives to animal testing: a review", Saudi Pharm. J, 23, pp.223~229 (2015)
- Lee SH, "Determination of thyroidal endocrine-disrupting chemicals (EDCs)activities using a human cell-based transactivation assay", Environ. Sci. Eur, 34, pp.51~ (2022)
- Lee S-H, "Development and characterization of a human cell line-based transactivation assay to assess thyroid EDCs", Environ. Res, 182, pp.109110~ (2020)
- van Vugt-Lussenburg BM, "Incorporation of metabolic enzymes to improve predictivity of reporter gene assay results for estrogenic and anti-androgenic activity", Reprod. Toxicol, 75, pp.40~48 (2018)
- Park SJ, "Integrative metabolomics reveals unique metabolic traits in Guillain-Barré syndrome and its variants", Sci. Rep, 9, pp.1077~ (2019)
- Yu JS, "Lactobacillus lactis and Pediococcus pentosaceus‐driven reprogramming of gut microbiome and metabolome ameliorates the progression of non‐alcoholic fatty liver disease", Clin. Transl. Med, 11, pp.e634~ (2021)
- Park SJ, "Exposure of ultrafine particulate matter causes glutathione redox imbalance in the hippocampus: A neurometabolic susceptibility to Alzheimer's pathology", Sci. Total Environ, 718, pp.137267~ (2020)
- Cerrato A, "A new software-assisted analytical workflow based on high-resolution mass spectrometry for the systematic study of phenolic compounds in complex matrices", Talanta, 209, pp.120573~ (2020)
- Montone CM, "Improved identification of phytocannabinoids using a dedicated structure-based workflow", Talanta, 219, pp.121310~ (2020)
- Simonato M, "Urinary metabolomics reveals kynurenine pathway perturbation in newborns with transposition of great arteries after surgical repair", Metabolomics, 15, pp.145~ (2019)
- Wang X, "An integrated approach to characterize intestinal metabolites of four phenylethanoid glycosides and intestinal microbe-mediated antioxidant activity evaluation in vitro using UHPLC-Q-Exactive High-Resolution Mass Spectrometry and a 1, 1-Diphenyl-2-picrylhydrazyl-based assay", Front. Pharmacol, 10, pp.826~ (2019)
- Howe E, "Biomedical informatics for cancer research", pp.267~277 (2010), Springer
- Nothias LF, "Feature-based molecular networking in the GNPS analysis environment", Nat. Methods, 17, pp.905~908 (2020)
- Wang M, "Sharing and community curation of mass spectrometry data with global natural products social molecular networking", Nat. Biotechnol, 34, pp.828~837 (2016)
- Aron AT, "Reproducible molecular networking of untargeted mass spectrometry data using GNPS", Nat. Protocols, 15, pp.1954~1991 (2020)
- Tsugawa H, "MS-DIAL: data-independent MS", MS deconvolution for comprehensive metabolome analysis, 2015, pp.12, 523~526
- Neto FC, "Expanding urinary metabolite annotation through integrated mass spectral similarity networking", Anal. Chem, 93, pp.12001~12010 (2021)
- Ernst M, "MolNetEnhancer: enhanced molecular networks by integrating metabolome mining and annotation tools", Metabolites, 9, pp.144~ (2019)
- Djoumbou Feunang Y, "ClassyFire: automated chemical classification with a comprehensive, computable taxonomy", J. Cheminform, 8, pp.61~ (2016)
- Djoumbou-Feunang Y, "BioTransformer: a comprehensive computational tool for small molecule metabolism prediction and metabolite identification", J. Cheminform, 11, pp.2~ (2019)
- Ridder L, "SyGMa: combining expert knowledge and empirical scoring in the prediction of metabolites", ChemMedChem, 3, pp.821~832 (2008)
- Tong Z, "In vitro glucuronidation of thyroxine and triiodothyronine by liver microsomes and recombinant human UDP-glucuronosyltransferases", Drug Metab. Dispos, 35, pp.2203~2210 (2007)
- Moreno M, "Metabolic effects of thyroid hormone derivatives", Thyroid, 18, pp.239~253 (2008)
- Knights KM, "Amino acid conjugation: contribution to the metabolism and toxicity of xenobiotic carboxylic acids", Exp. Opin. Drug Metab. Txicol, 3, pp.159~168 (2007)
- Mondal S, "Chemistry and biology in the biosynthesis and action of thyroid hormones", Angew. Chemi. Int. Ed. Engl, 55, pp.7606~7630 (2016)
- Flock EV, "Metabolic pathways of tetraiodothyroacetic acid, triiodothyroacetic acid, tetraiodothyropropionic acid and triiodothyropropionic acid", Biochem. Pharmacol, 11, pp.627~637 (1962)
- Quinn RA, "Molecular networking as a drug discovery, drug metabolism, and precision medicine strategy", Trends Pharmacol. Sci, 38, pp.143~154 (2017)
- Yu JS, "Tandem mass spectrometry molecular networking as a powerful and efficient tool for drug metabolism studies", Anal. Chem, 94, pp.1456~1464 (2022)
- Taurog A, "Myeloperoxidase-catalyzed iodination and coupling", Arch. Biochem. Biophys, 296, pp.239~246 (1992)
- La Perle KM, "Iodine: Symporter and oxidation, thyroid hormone biosynthesis", Thyroid Hormone Biosynthesis, 2023, pp.517~522 (2003)
- Kang JH, "Biodegradation or metabolism of bisphenol A: from microorganisms to mammals", Toxicology, 217, pp.81~90 (2006)
- Schlecht C, "Pharmacokinetics and metabolism of benzophenone 2 in the rat", Toxicology, 245, pp.11~17 (2008)
- Mueck AO, "Estradiol metabolism and malignant disease", Maturitas, 43, pp.1~10 (2002)
- Walle T, "Absorption and metabolism of flavonoids", Free Rad. Biol. Med, 36, pp.829~837 (2004)
- Gradolatto A, "Metabolism of apigenin by rat liver phase I and phase II enzymes and by isolated perfused rat liver", Drug Metab. Dispos, 32, pp.58~65 (2004)
- Wen L, "Structure, bioactivity, and synthesis of methylated flavonoids", Ann. NY Acad. Sci, 1398, pp.120~129 (2017)
- Tarui H, "Metabolism of procymidone derivatives in female rats", J. Agric. Food Chem, 57, pp.10883~10888 (2009)
- Swan G, "The pharmacology of halogenated salicylanilides and their anthelmintic use in animals", J. S. Afr. Vet. Assoc, 70, pp.61~70 (1999)
- Deng P, "Identification of amiodarone metabolites in human bile by ultraperformance liquid chromatography", quadrupole time-of-flight mass spectrometry, 2011, pp.39, 1058~1069